Acorda Therapeutics, Inc Earning Date (ACOR)

USA |NASDAQ |USD

ACOR Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $-2.29
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $31.79M

Acorda Therapeutics, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

ACOR Earnings Date & History Chart

ACOR Earnings & Revenue Forecast

ACOR Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 0 $0.00 $0.00 $0.00

ACOR Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-0.96 $-0.96 $-0.96

ACOR Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 1 $120.51M $120.51M $120.51M

ACOR Earnings Date & Revenue History

ACOR Earnings History

|
Show More
Show More

ACOR Revenue History

|
Show More
Show More

Acorda Therapeutics, Inc Next Earnings Date & Report

ACOR Next Earnings Date & Report Preview: Jun 2022 (FQ)

ACOR's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Acorda Therapeutics, Inc Previous Earnings Dates & Reports

ACOR Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Acorda Therapeutics, Inc's previous earnings date was May 11, 2022 for its fiscal quarter ended Mar 31, 2022.

ACOR Previous Earnings Date & Report Recap: Dec 2021 (FY)

Acorda Therapeutics, Inc's previous annual earnings date was Mar 9, 2022 for its fiscal year ended Dec 31, 2021.

ACOR's earnings per share (EPS) was $-9.98, missing the consensus analysts forecast of $0.00 by % , and higher than the previous year's EPS (Dec 2020) by -20.63%.

Revenues were $129.07M, better than the forecast of $129.07M by 0.00%, and down by -15.62% from previous year's revenue.

The company reported a net income of $-103.95M.

Acorda Therapeutics, Inc reported a free cash flow of $5.02M for its fiscal year, compared to $-65.40M a year ago.

The company ended the fiscal year with $159.21M in total debt, a decrease of -36.66% compared to the previous year.